三氧化二砷联合化疗治疗难治性及复发性恶性血液病的临床疗效探究

Clinical Effect of Arsenic Trioxide combined with Chemotherapy for Treatment of Refractory and Recurrent Hematologic Malignancies

目的探究三氧化二砷联合化疗治疗难治性及复发性恶性血液病的临床效果,为患者的治疗寻找最有效的方式。方法将2012年3月—2015年3月该院收治的80例难治性及复发性恶性血液病患者为研究对象,按照治疗方式的不同分为对照组与观察组各40例,对照组给予单纯化疗,观察组在此基础上给予三氧化二砷联合治疗,比较两组的治疗效果与不良反应。结果观察组患者治疗后的总有效率(87.5%)显著高于对照组(65.0%)(P<0.05),且毒副反应的发生率(27.5%)显著低于对照组(65.0%)(P<0.05)。结论三氧化二砷联合化疗治疗难治性及复发性恶性血液病临床效果显著,且治疗过程中出现的毒副反应少,是一种值得借鉴的临床治疗方式。

Objective To explore the clinical effect of arsenic trioxide combined with chemotherapy for treatment of refractory and recurrent hematologic malignancies so as to optimize its treatment. Methods 80 patients with refractory and recurrent hematologic malignancies admitted in our hospital from March 2012 and March 2015 were selected as the research object and divided into control group and observation group according to therapeutic schemes. Single chemotherapy was performed in the control group while arsenic trioxide combined with chemotherapy was used in the observation group. The clinical effects and adverse reactions were compared between the two groups. Results The total effective rate was significantly higher and the incidence of adverse reactions significantly lower, in the observation group than in the control group, 87.5% vs 65.0% and 27.5% vs 65.0%, respectively,and the differences were statistically significant（P〈0.05）. Conclusion The clinical effect of arsenic trioxide combined with chemotherapy for treatment of refractory and recurrent hematologic malignancies is remarkable, which shows less adverse reaction.Therefore it is worthy of application.